Cancer is not a single disease. It consists of a dozen types and countless subtypes. Researchers need a critical mass of samples (i.e., biospecimens) to fully understand the pathology of each type and to predict better how tumors will behave and respond to targeted treatments. We are working to make the biospecimen workflow more patient-centred so more people with cancer can donate to research.

A significant number of cancer types are highly-aggressive and continue to show poor outcomes with standard-of-care treatment. Our newly formed multi-disciplinary team will perform molecular profiling of these aggressive solid tumour subtypes at their earliest stages (prior to any treatment) and identify opportunities for new multiomics data-driven drug interventions and/or clinical trials that may alter treatment trajectories and outcomes.